Latest Advances in Lung Cancer Research

Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.

Removing only a portion of lobes is as effective as the traditional surgery for some patients with early-stage lung cancer.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.

Deep-learning model takes a personalized approach to assessing each patient’s risk of lung cancer based on CT scans.

Lung cancer screening may accelerate the shift of the lung cancer stage from an advanced incurable stage toward an early curable disease, which may improve survival.

67% of small smoke particles in the US are due to human-ignited fires are responsible for degrade air quality, causing respiratory illnesses, and premature death.

Mirati’s new lung cancer drug Krazati, targeting KRAS mutations, secures FDA approval, offering hope for advanced NSCLC patients.

The diagnosis of early-stage lung cancer with low-dose CT screening led to high rates of lung cancer-specific survival two decades later.

Mirati’s adagrasib and Keytruda show promise for KRAS G12C-mutated NSCLC with a 49% tumor shrinkage in trials.